Sprint Bioscience: Announces rights issue

Research Note

2022-09-22

13:01

Redeye comments on Sprint Bioscience announcing a rights issue. The capital raise aligns with our expectations but comes at a lower subscription price than we estimated earlier this year. We will adjust our estimates and valuation once the company communicates the rights issue’s outcome in mid-November.

CB

Christian Binder

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.